

DNA, Mumbai

Friday 12th December 2014, Page: 12

Width: 5.86 cms, Height: 5.00 cms, a4, Ref: pmin.2014-12-13.25.42

Lupin launches generic version of Celebrex in US market

Lupin has launched in the US market the generic version of Celebrex capsules used for treatment of osteoarthritis, rheumatoid arthritis and acute pain. Its US subsidiary, Lupin Pharmaceuticals Inc has launched the authorised generic for GD Searle LLC's (a subsidiary of Pfizer) Celebrex capsules of strength of 50 mg, 100 mg, 200 mg and 400 mg. Lupin had earlier signed a licensing agreement with Pfizer Inc for Celebrex, which has an annual sales of \$2.54 billion in US market.

Company